Premium
Olanzapine in the treatment of anorexia nervosa: An open label trial
Author(s) -
Powers Pauline S.,
Santana Carlos A.,
Ban Yvonne S.
Publication year - 2002
Publication title -
international journal of eating disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.785
H-Index - 138
eISSN - 1098-108X
pISSN - 0276-3478
DOI - 10.1002/eat.10084
Subject(s) - olanzapine , anorexia nervosa , weight gain , psychoeducation , psychology , schizoaffective disorder , atypical antipsychotic , schizophrenia (object oriented programming) , psychiatry , open label , bipolar disorder , medicine , pediatrics , psychosis , antipsychotic , eating disorders , randomized controlled trial , body weight , lithium (medication) , psychological intervention
Objective The primary goal of the study was to determine if olanzapine is effective in producing weight gain in patients with anorexia nervosa. Method Twenty patients with anorexia nervosa (restricting or binge/purge subtype) without schizophrenia, schizoaffective disorder, or bipolar disorder enrolled in an open label study of olanzapine 10 mg. Patients attended weekly drug monitoring sessions and weekly group medication adherence sessions that provided psychoeducation. Results Eighteen patients received the drug and 14 patients completed the 10‐week study. The four drop‐outs had gained a mean of 3.25 lb at their last visit. Of the 14 patients who completed the study, 10 gained an average of 8.75 lb and 3 of these patients attained their ideal body weight. The remaining four patients who completed the study lost a mean of 2.25 lb. Discussion These findings are promising with clinically significant weight gain in an outpatient setting during a brief 10‐week period. © 2002 by Wiley Periodicals, Inc. Int J Eat Disord 32: 146–154, 2002.